BRAF and melanoma: Among the most established therapies targeting the BRAFV600E mutation site are vemurafenib (approved in 2011) and dabrafenib (approved in 2013), which serve as first-line treatments for advanced BRAF-mutant melanoma (Garbe and Eigentler, 2018; Long et al., 2024).